U.S. License Holder:
Lundbeck Seattle BioPharmaceuticals, Inc.
Date of License:
February-21-2020
Last Update:
Dec-15-2024
FDA-Approved Indications
VYEPTI (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.